Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)
China
· Delayed Price · Currency is CNY 24.15
-0.41 (-1.67%)
Mar 9, 2026, 3:04 PM CST
SHE:300357 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 1,045 | 921.46 | 840.75 | 894.88 | 804.12 | 633.42 | Upgrade
|
| Other Revenue | 3.94 | 3.94 | 7.44 | 1.14 | 3.58 | 2.79 | Upgrade
|
| Revenue | 1,049 | 925.39 | 848.19 | 896.02 | 807.69 | 636.21 | Upgrade
|
| Revenue Growth (YoY) | 15.90% | 9.10% | -5.34% | 10.94% | 26.95% | -0.49% | Upgrade
|
| Cost of Revenue | 49.65 | 44.81 | 40.19 | 42.51 | 34.44 | 28.54 | Upgrade
|
| Gross Profit | 998.87 | 880.58 | 808 | 853.5 | 773.25 | 607.67 | Upgrade
|
| Selling, General & Admin | 461.41 | 434.65 | 385.28 | 359.63 | 333.97 | 263.18 | Upgrade
|
| Research & Development | 117.72 | 119.88 | 112.2 | 106.02 | 87.93 | 61.27 | Upgrade
|
| Other Operating Expenses | 18.97 | 7.84 | 4.57 | 4.53 | 3.78 | 3.27 | Upgrade
|
| Operating Expenses | 600.05 | 563.23 | 501.05 | 471.43 | 427.23 | 328.01 | Upgrade
|
| Operating Income | 398.82 | 317.36 | 306.95 | 382.07 | 346.02 | 279.66 | Upgrade
|
| Interest Expense | -0.76 | -1.06 | -1.31 | -0.44 | -0.36 | - | Upgrade
|
| Interest & Investment Income | 26.87 | 35.81 | 32.87 | 28.35 | 29.03 | 24.63 | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | 0 | 0 | -0 | -0 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.44 | -0.34 | -0.26 | -0.15 | -0.17 | -0.17 | Upgrade
|
| EBT Excluding Unusual Items | 427.36 | 351.76 | 338.25 | 409.82 | 374.52 | 304.11 | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.82 | 2.43 | -0.67 | -0.88 | -0.1 | 2.66 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.63 | 0.57 | - | -0.27 | - | - | Upgrade
|
| Asset Writedown | -1.42 | -1.42 | -0.58 | -43.23 | -0.1 | -0.01 | Upgrade
|
| Other Unusual Items | 14.41 | 11.72 | 8.95 | 33.3 | 18.67 | 15.85 | Upgrade
|
| Pretax Income | 445.82 | 365.06 | 345.96 | 398.75 | 393 | 322.62 | Upgrade
|
| Income Tax Expense | 68.74 | 60.72 | 50.43 | 63.02 | 66.71 | 52.89 | Upgrade
|
| Earnings From Continuing Operations | 377.08 | 304.34 | 295.52 | 335.73 | 326.29 | 269.72 | Upgrade
|
| Minority Interest in Earnings | 13.36 | 13.48 | 14.66 | 13.05 | 11.7 | 8.72 | Upgrade
|
| Net Income | 390.43 | 317.82 | 310.18 | 348.77 | 337.99 | 278.45 | Upgrade
|
| Net Income to Common | 390.43 | 317.82 | 310.18 | 348.77 | 337.99 | 278.45 | Upgrade
|
| Net Income Growth | 25.02% | 2.46% | -11.06% | 3.19% | 21.38% | -6.65% | Upgrade
|
| Shares Outstanding (Basic) | 524 | 524 | 524 | 524 | 524 | 524 | Upgrade
|
| Shares Outstanding (Diluted) | 524 | 524 | 524 | 524 | 524 | 524 | Upgrade
|
| Shares Change (YoY) | -0.01% | -0.00% | - | -0.00% | 0.00% | -0.00% | Upgrade
|
| EPS (Basic) | 0.75 | 0.61 | 0.59 | 0.67 | 0.65 | 0.53 | Upgrade
|
| EPS (Diluted) | 0.75 | 0.61 | 0.59 | 0.67 | 0.65 | 0.53 | Upgrade
|
| EPS Growth | 25.03% | 2.46% | -11.06% | 3.19% | 21.38% | -6.65% | Upgrade
|
| Free Cash Flow | 246.92 | 133.12 | 154.61 | 159.62 | 236.33 | 186.06 | Upgrade
|
| Free Cash Flow Per Share | 0.47 | 0.25 | 0.29 | 0.30 | 0.45 | 0.35 | Upgrade
|
| Dividend Per Share | 0.220 | 0.220 | 0.185 | 0.200 | 0.201 | 0.160 | Upgrade
|
| Dividend Growth | -22.81% | 18.92% | -7.50% | -0.50% | 25.62% | -11.11% | Upgrade
|
| Gross Margin | 95.27% | 95.16% | 95.26% | 95.25% | 95.74% | 95.51% | Upgrade
|
| Operating Margin | 38.04% | 34.29% | 36.19% | 42.64% | 42.84% | 43.96% | Upgrade
|
| Profit Margin | 37.24% | 34.34% | 36.57% | 38.92% | 41.85% | 43.77% | Upgrade
|
| Free Cash Flow Margin | 23.55% | 14.39% | 18.23% | 17.82% | 29.26% | 29.25% | Upgrade
|
| EBITDA | 451.29 | 360.81 | 338.38 | 402.44 | 366.11 | 294.68 | Upgrade
|
| EBITDA Margin | 43.04% | 38.99% | 39.89% | 44.91% | 45.33% | 46.32% | Upgrade
|
| D&A For EBITDA | 52.47 | 43.45 | 31.43 | 20.37 | 20.08 | 15.03 | Upgrade
|
| EBIT | 398.82 | 317.36 | 306.95 | 382.07 | 346.02 | 279.66 | Upgrade
|
| EBIT Margin | 38.04% | 34.29% | 36.19% | 42.64% | 42.84% | 43.96% | Upgrade
|
| Effective Tax Rate | 15.42% | 16.63% | 14.58% | 15.80% | 16.97% | 16.39% | Upgrade
|
| Revenue as Reported | 1,049 | 925.39 | 848.19 | 896.02 | 807.69 | 636.21 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.